Hypertensive nephropathy primary prevention: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
mNo edit summary |
||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Hypertensive nephropathy}} | {{Hypertensive nephropathy}} | ||
*Renin–angiotensin–aldosterone (RAAS) blockers such as [[ACEI]] or [[ARB]] play a significant role in preventing progression to [[ESRD]] by controlling blood pressure in hypertensive patients. | |||
*According to 2017 guidelines, the goal of BP is < 130/80 mmHg for patients with hypertension and [[CKD]] regardless of [[proteinuria]].<ref>{{cite journal|title=Correction|journal=Journal of the American College of Cardiology|volume=71|issue=19|year=2018|pages=2275–2279|issn=07351097|doi=10.1016/j.jacc.2018.03.016}}</ref> | |||
==References== | ==References== | ||
{{reflist|2}} | {{reflist|2}} | ||
Revision as of 15:13, 18 June 2020
|
Hypertensive nephropathy Microchapters |
|
Differentiating Hypertensive Nephropathy from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Hypertensive nephropathy primary prevention On the Web |
|
American Roentgen Ray Society Images of Hypertensive nephropathy primary prevention |
|
Risk calculators and risk factors for Hypertensive nephropathy primary prevention |
- Renin–angiotensin–aldosterone (RAAS) blockers such as ACEI or ARB play a significant role in preventing progression to ESRD by controlling blood pressure in hypertensive patients.
- According to 2017 guidelines, the goal of BP is < 130/80 mmHg for patients with hypertension and CKD regardless of proteinuria.[1]
References
- ↑ "Correction". Journal of the American College of Cardiology. 71 (19): 2275–2279. 2018. doi:10.1016/j.jacc.2018.03.016. ISSN 0735-1097.